COMMUNIQUÉS West-GlobeNewswire

Hydrafacial Introduces HydraClear™ Treatment Booster to Clarify Blemish-Prone Skin
06/10/2026
New triple-acid treatment booster is designed to help clarify, balance, and fade visible signs of blemish-prone skin while helping maintain hydration LONG BEACH, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- SkinHealth [...]
Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026
06/10/2026
NORCROSS, Ga., Oct. 06, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced participation in the upcoming AASLD Liver [...]
Stryker announces leadership succession
06/10/2026
Portage, Michigan, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Kevin Lobo to transition to Executive Chair of the Board of Directors Current President and COO Spencer Stiles appointed Chief Executive Officer Leadership transition [...]
PDS Biotech to Host Key Opinion Leader Event on PDS0301 for the Treatment of Advanced Colorectal Cancer with Liver Metastases
06/10/2026
Virtual Event Featuring Jonathan M. Hernandez, M.D, Investigator, Surgical Oncology Program, NCI/CCR, to Be Held October 15, 2026, at 8am ET PRINCETON, N.J., Oct. 06, 2026 (GLOBE NEWSWIRE) -- PDS Biotechnology [...]
Telomir Pharmaceuticals Secures $5.6 Million Financing as Billionaire Entrepreneur John Paul DeJoria Increases Investment in the Company
06/10/2026
Common Stock PIPE Strengthens Telomir’s Capital Position as Company Advances Telomir-Zn into Clinical Development Under FDA-Cleared IND in Triple-Negative Breast Cancer (TNBC) MIAMI, Oct. 06, 2026 (GLOBE NEWSWIRE) -- [...]
Oak Hill Bio Appoints Joerg Hipp, PhD as Chief Translational Science Officer
06/10/2026
CAMBRIDGE, Mass., Oct. 06, 2026 (GLOBE NEWSWIRE) -- OHB Pediatrics Ltd d/b/a Oak Hill Bio, a clinical-stage rare disease therapeutics company, today announced the appointment of Joerg Hipp, PhD as Chief Translational [...]
Odyssey Therapeutics Announces Oral Presentation of Additional Phase 2a Induction Data for OD-001 in Ulcerative Colitis at UEG Week 2026
06/10/2026
Company to host conference call and webcast following the presentation on Tuesday, October 20, at 8:00 a.m. EDT BOSTON, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “ [...]
vTv Therapeutics to Host Virtual KOL Event on Hypoglycemia in Type 1 Diabetes and the Cadisegliatin Phase 3 Program on October 20, 2026
06/10/2026
HIGH POINT, N.C., Oct. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), [...]
YD Bio and EG BioMed Launch AI-Based 10-Cancer Risk Factor Assessment
06/10/2026
TAIPEI, Taiwan, and BOTHELL, Wash., Oct. 06, 2026 (GLOBE NEWSWIRE) -- YD Bio Limited (“YD Bio” or the “Company”) (Nasdaq: YDES), a biotechnology company advancing DNA methylation-based cancer detection technology and [...]
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
06/10/2026
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies TEL AVIV, Israel, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Entera Bio Ltd. ( [...]
LB Pharmaceuticals to Host In-Person and Virtual R&D Day on October 27, 2026: Advancing LB‑102 with a Focus on Schizophrenia Treatment
06/10/2026
NEW YORK, Oct. 06, 2026 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals” or the “Company”) (Nasdaq: LBRX), a neuromedicines company dedicated to developing and commercializing high-impact therapies that [...]
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
06/10/2026
CALGARY, Alberta, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Marvel Biosciences Corp. (TSXV: MRVL | OTCQB: MBCOF) , and its wholly-owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), a drug [...]
Nox Peptides Announces Launch of GHK-Cu and Wolverine Stack for Canadian Research Market
06/10/2026
TORONTO, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Nox Peptides today announced the launch of two research-focused peptide products, GHK-Cu and the Wolverine Stack , expanding its product offering for Canadian laboratories, [...]
Quoin Pharmaceuticals Announces Acceptance of QRX003 Paper in Dermatology and Therapy
06/10/2026
Peer-Reviewed Paper Introduces QRX003 and Its Mechanism of Action in Netherton Syndrome Case Report Details Professor Alan Irvine’s Clinical Experience Treating a Pediatric Patient Under Quoin’s Compassionate Use [...]
First Patients Dosed with Telix’s FDA-Approved Brain Cancer Imaging Drug Pixclara® (floretyrosine F 18)
06/10/2026
First doses of Pixclara administered in Cleveland (OH) and Indianapolis (IN) marking the start of U.S. commercial availability. Pixclara is the only FDA-approved radiopharmaceutical imaging drug for glioma (brain cancer [...]
MediciNova to Participate in the Maxim Growth Summit
06/10/2026
LA JOLLA, Calif., Oct. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875 [...]
Smith+Nephew’s revolutionary CARTIHEAL™ AGILI-C™ Cartilage Repair Implant launches in Europe; to be featured at ICRS Summit in Portugal
06/10/2026
Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology company, today announces that its innovative CARTIHEAL AGILI-C Cartilage Repair Implant is now commercially available in Europe. The CARTIHEAL Implant will [...]
Smith+Nephew lancia in Europa CARTIHEAL™ AGILI-C™, l’innovativo impianto per la riparazione della cartilagine, che sarà presentato all’ICRS Summit in Portogallo.
06/10/2026
Smith+Nephew (LSE: SN, NYSE: SNN) azienda di tecnologia medica, annuncia il lancio commerciale in Europa di CARTIHEAL AGILI-C, l’innovativo impianto per la riparazione della cartilagine. La tecnologia sarà presentata [...]
Transactions in connection with share buy-back program
06/10/2026
Company announcement no. 38 - 26 06 October 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as described in company [...]

Pages